TSEN-FANG TSAIChoon S.-E.Marrakchi S.David Burden A.Morita A.Turki H.Hall D.B.Shear M.Baum P.Padula S.J.Thoma C.2019-07-112019-07-112019-03-070028-4793https://scholars.lib.ntu.edu.tw/handle/123456789/413480en[SDGs]SDG3bi 655130; cytokine; cytokine receptor antagonist; interleukin 36; monoclonal antibody; unclassified drug; IL36RN protein, human; interleukin derivative; interleukin receptor; interleukin-36 receptor, human; drug efficacy; gene; gene mutation; generalized pustular psoriasis; generalized pustular psoriasis; human; IL36RN gene; Letter; priority journal; proof of concept; pustular psoriasis; antagonists and inhibitors; clinical trial; female; genetics; intravenous drug administration; male; metabolism; mutation; phase 1 clinical trial; psoriasis; severity of illness index; Administration, Intravenous; Female; Humans; Interleukins; Male; Mutation; Psoriasis; Receptors, Interleukin; Severity of Illness Indexjournal article10.1056/NEJMc1811317308557492-s2.0-85062722357WOS:000460461500015https://api.elsevier.com/content/abstract/scopus_id/85062722357